Trial Profile
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Venetoclax (Primary) ; Pomalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms CANOVA
- Sponsors AbbVie; AbbVie Germany
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2023 Planned End Date changed from 25 Oct 2025 to 25 Feb 2026.
- 30 Oct 2023 Planned primary completion date changed from 25 Oct 2025 to 25 Feb 2026.